AONC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AONC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
American Oncology Network has the Financial Strength Rank of 5.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.American Oncology Network did not have earnings to cover the interest expense. American Oncology Network's debt to revenue ratio for the quarter that ended in Jun. 2024 was 0.08. As of today, American Oncology Network's Altman Z-Score is 2.92.
For the Medical Care Facilities subindustry, American Oncology Network's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Healthcare Providers & Services industry and Healthcare sector, American Oncology Network's Financial Strength distribution charts can be found below:
* The bar in red indicates where American Oncology Network's Financial Strength falls into.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
American Oncology Network's Interest Expense for the months ended in Jun. 2024 was $-2 Mil. Its Operating Income for the months ended in Jun. 2024 was $-7 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $134 Mil.
American Oncology Network's Interest Coverage for the quarter that ended in Jun. 2024 is
American Oncology Network did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
American Oncology Network's Debt to Revenue Ratio for the quarter that ended in Jun. 2024 is
Debt to Revenue Ratio | = | Total Debt (Q: Jun. 2024 ) | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (12.512 | + | 134.408) | / | 1735.928 | |
= | 0.08 |
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
American Oncology Network has a Z-score of 2.92, indicating it is in Grey Zones. This implies that American Oncology Network is in some kind of financial stress. If it is below 1.81, the company may faces bankrupcy risk.
Warning Sign:
Altman Z-score of 2.92 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
American Oncology Network (OTCPK:AONC) Financial Strength Explanation
The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.
American Oncology Network has the Financial Strength Rank of 5.
Thank you for viewing the detailed overview of American Oncology Network's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.
Saba Capital Management, L.p. | 10 percent owner | 405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174 |
Boaz Weinstein | 10 percent owner | 405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174 |
David H Gould | officer: Chief Financial Officer | 7370 COLLEGE PARKWAY, SUITE 207, FORT MEYERS FL 33907 |
Erica Mallon | officer: General Counsel | 14543 GLOBAL PARKWAY, SUITE 110, FORT MEYERS FL 33913 |
Shalin Shah | director | 3402 W DR. MARTIN LUTHER KING JR. BLVD, TAMPA FL 33607 |
Vipul M Patel | director | 11704 SE 15TH CIRCLE, OCALA FL 34480 |
Todd Schonherz | director, officer: Chief Executive Officer | 14543 GLOBAL PARKWAY, 2ND FLOOR, FORT MEYERS FL 33913 |
Stephen Divers | director, officer: Chief Medical Officer | 133 HARMONY PARK CIRCLE, HOT SPRINGS AZ 71913 |
Vance Wright-browne | director | 22395 EDGEWATER DRIVE, PORT CHARLOTTE FL 33980 |
James Stith | director | ONE LETTERMAN DRIVE, CM200, SAN FRANCISCO CA 94129 |
Aea Growth Equity Fund Lp | 10 percent owner | 520 MADISON AVE, 40TH FLOOR, NEW YORK NY 10022 |
Aea Growth Equity Fund (parallel) Lp | 10 percent owner | 520 MADISON AVE, 40TH FLOOR, NEW YORK NY 10022 |
Ravi Yang Sarin | director | C/O ARES MANAGEMENT LLC, 2000 AVENUE OF THE STARS, 12TH FLOOR, LOS ANGELES CA 90067 |
Brian R Hoesterey | 10 percent owner | C/O AEA INVESTORS LP, 666 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10103 |
Kevin Nazemi | director, officer: Chief Executive Officer | 10485 NE 6TH ST, UNIT 3930, BELLEVUE WA 98004 |
From GuruFocus
By Marketwired • 09-20-2023
By Marketwired • 09-27-2023
By Marketwired • 11-02-2023
By Marketwired • 11-07-2023
By Marketwired • 10-18-2023
By Marketwired • 10-11-2023
By Marketwired • 10-25-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.